Codice QR

PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs

PCSK9 has now become an important target to create new classes of lipid-lowering drugs. The prevention of its interaction with LDL receptors allows an increase in the number of these receptors on the surface of the cell membrane of hepatocytes, which leads to an increase in the uptake of cholesterol...

Descrizione completa

Salvato in:
Autori principali: Nikolay Kuzmich, Elena Andresyuk, Yuri Porozov, Vadim Tarasov, Mikhail Samsonov, Nina Preferanskaya, Valery Veselov, Renad Alyautdin
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI AG 2022-01-01
Serie:Molecules
Soggetti:
PCSK9
LDLR
antihyperlipidemic therapy
lipid-lowering drugs
PCSK9 inhibitors
Accesso online:https://www.mdpi.com/1420-3049/27/2/434
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi